Navigation Links
Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference

CASTLE ROCK, Colo., Aug. 5, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity 34th Annual Growth Conference, to be held August 13-14, 2014, at the Intercontinental Boston in Boston, MA.

Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business during his scheduled presentation and will be available for one-on-one meetings with investors who are registered to attend the conference. 

Event: Canaccord Genuity 34th Annual Growth Conference

Date: Thursday, August 14, 2014

Presentation Time: 1:00 pm (Eastern Time)

Location: Melbourne Room

The presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, multi-analyte assay for appendicitis.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, a limited commercial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-K for the year ended December 31, 2013, filed with the SEC on March 28, 2014.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

Contact – Jed Mahan,; (303) 794-2000 Ext. 255

SOURCE Venaxis, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
2. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
3. Venaxis Announces Pricing of Offering of Common Stock and Warrants
4. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
5. Ardelyx to Present at the Wedbush 2014 Life Sciences Management Access Conference
6. Intrexon to Present at Jefferies 2014 Global Industrials Conference
7. Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference
8. TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner
9. Dmitry Medvedev Presented BIOCAD the First National "Industry" Award
10. Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness"
11. Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase
Post Your Comments:
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
(Date:11/24/2015)... LOS ANGELES , Nov. 24, 2015 ... a biotechnology company focused on the discovery, development and ... Marban , Ph.D., Chief Executive Officer, is scheduled to ... December 1, 2015 at 10:50 a.m. EST, at The ... York City . . ...
Breaking Biology Technology:
(Date:10/27/2015)... JOSE, Calif. , Oct. 27, 2015 Synaptics ... interface solutions, today announced that Google has adopted the ... of touch controller solutions to power its newest flagship ... 6P by Huawei. --> ... partners like Google to provide strategic collaboration in the ...
(Date:10/26/2015)... NEWARK, Calif. , Oct. 26, 2015  Delta ... convenient biometric authentication to mobile and PC devices, announced ... Fujitsu,s smartphone, the arrows NX F-02H launched by NTT ... arrows NX F-02H is the second smartphone to include ... this technology in ARROWS NX F-04G in May 2015, ...
(Date:10/22/2015)... AWRE ), a leading supplier of biometrics software and services, ... 2015.  --> --> Revenue ... of 33% compared to $6.0 million in the same quarter last ... million, or $0.10 per diluted share, which compared to $2.6 million, ... ago.  --> --> Lower ...
Breaking Biology News(10 mins):